- Home
- BOW vs ARDX Comparison
BOW vs ARDX Comparison
Compare BOW & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOW
- ARDX
- Stock Information
- Founded
- BOW 2020
- ARDX 2007
- Country
- BOW United States
- ARDX United States
- Employees
- BOW N/A
- ARDX N/A
- Industry
- BOW Property-Casualty Insurers
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- BOW Finance
- ARDX Health Care
- Exchange
- BOW Nasdaq
- ARDX Nasdaq
- Market Cap
- BOW 1.2B
- ARDX 1.2B
- IPO Year
- BOW 2024
- ARDX 2014
- Fundamental
- Price
- BOW $35.59
- ARDX $4.64
- Analyst Decision
- BOW Hold
- ARDX Buy
- Analyst Count
- BOW 5
- ARDX 7
- Target Price
- BOW $32.00
- ARDX $11.75
- AVG Volume (30 Days)
- BOW 155.6K
- ARDX 3.4M
- Earning Date
- BOW 02-15-2025
- ARDX 10-31-2024
- Dividend Yield
- BOW N/A
- ARDX N/A
- EPS Growth
- BOW 130.44
- ARDX N/A
- EPS
- BOW 1.08
- ARDX N/A
- Revenue
- BOW $389,135,000.00
- ARDX $251,849,000.00
- Revenue This Year
- BOW N/A
- ARDX $168.07
- Revenue Next Year
- BOW $25.16
- ARDX $15.16
- P/E Ratio
- BOW $32.87
- ARDX N/A
- Revenue Growth
- BOW 107.43
- ARDX 87.57
- 52 Week Low
- BOW $22.14
- ARDX $4.34
- 52 Week High
- BOW $37.81
- ARDX $10.13
- Technical
- Relative Strength Index (RSI)
- BOW N/A
- ARDX 34.51
- Support Level
- BOW N/A
- ARDX $5.18
- Resistance Level
- BOW N/A
- ARDX $5.47
- Average True Range (ATR)
- BOW 0.00
- ARDX 0.32
- MACD
- BOW 0.00
- ARDX -0.07
- Stochastic Oscillator
- BOW 0.00
- ARDX 3.28
About BOW Bowhead Specialty Holdings Inc. Common Stock
Bowhead Specialty Holdings Inc is engaged in providing specialty P&C products. It is a specialty insurance group that generates revenues by underwriting and offering a variety of specialty insurance products to domestic markets through three distinct underwriting divisions: Casualty, Professional Liability and Healthcare. Casualty specialize in GL coverage for risks in the construction, distribution, heavy manufacturing, real estate and hospitality segments and also consider underwriting risks in a broader range of industries. Key revenue is generated from Casualty segment.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.